Organoids Inform an Aggressive Approach to Pancreatic Cancer
This activity has been archived and credit is no longer available.
In this presentation, Dr. Richard Burkhart discusses his laboratory and clinical work in the application of surgical techniques for patients with pancreatic cancer, particularly those with cancer that has been classified as unresectable or locally advanced.
This Hematology and Oncology Grand Rounds session took place on Friday, September 16, 2022 at 12:30 p.m.
Activity Information
This activity has been archived and credit is no longer available.
Needs Statement
Medical oncologists, hematologists, gastroenterologists, pulmonologists, internists, surgeons, geneticists, palliative care specialists, basic and translational research scientists, residents, fellows, and medical students need to receive regular updates on advances in the diagnosis and management of hematologic disorders and malignancies. The series aims to expand the knowledge base of learners in these topic areas, improve their clinical competencies and research skills, enhance patient care, and improve outcomes.
Educational Objectives
At the conclusion of the session, the participants should be able to:
- Describe standard of care treatments for sequencing and treatment options for patients with pancreatic cancer.
- Discuss the emerging options for predictive biomarkers of therapeutic response in pancreatic cancer.
- Identify patients eligible for multi-modal therapies, including radiotherapeutic and surgical approaches, in pancreatic cancer.
Target Audience
Professional Categories
- Physicians
- Medical Students
- Fellows
- Residents
- Other Health Professionals
Specialties
- Gastroenterology and Hepatology
- Oncology
- Surgical Oncology
Interest Groups
Accreditation/Credit Designation
Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Baylor College of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Activity Director
Term of Approval
September 1, 2022 through September 30, 2024. Original release date: September 1, 2022.
Disclosure Policy
Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.
In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.
In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.
BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
The following individual(s) has/have reported financial or other relationship(s) with commercial entities whose products/services may relate to the educational content of this activity:
Presenter
-
Richard Burkhart, M.D.
Associate Professor
Johns Hopkins University
Disclosure:
Nothing to disclose.
Activity Director
-
Tannaz Armaghany, M.D.
Assistant Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
Planning Committee Members
-
Tannaz Armaghany, M.D.
Assistant Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Salma Kaochar, M.D.
Assistant Professor
Baylor College of Medicine
Disclosure:
- Research Support: FGH Biotech; Systems Oncology; National Institutes of Health; National Cancer Center; Department of Defense; Prostate Cancer Foundation
- Consultancy: FGH Biotech; Systems Oncology
- Intellectual Property: Baylor College of Medicine
-
Meera Patel, M.D., M.H.S.
Assistant Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Daniel Y. Wang, M.D.
Assistant Professor
Baylor College of Medicine, Dan L. Duncan Comprehensive Cancer Center
Disclosure:
- Research Support: Tessa Therapeutics
- Advisory Committee Membership: Regeneron; Sanofi-Genzyme
- Honorarium Recipient: Pri-Med
-
Yang Zhou, M.D.
Hematology and Oncology Fellow
Baylor College of Medicine
Disclosure:
Nothing to disclose.
Health Topics
Presenter: